Key result
Prolonged prostaglandin-E2 therapy in infants with congenital cardiac lesions was associated with periosteal reactions and elevated C-reactive protein levels.
Why the study?
Does prolonged prostaglandin-E2 therapy cause periosteal reactions and elevated C-reactive protein levels in infants with congenital cardiac lesions?
Case Report (n=2)
Does prolonged prostaglandin-E2 therapy cause periosteal reactions and elevated C-reactive protein levels in infants with congenital cardiac lesions?
Clinicians should be aware that prolonged prostaglandin-E2 therapy can cause periosteal reactions and elevated CRP, avoiding unnecessary antibiotics for presumed sepsis.
Answers are grounded in this paper and cite their sources.
May warrant monitoring during prolonged prostaglandin-E2 use; leaves open causality and practice implications.
This is a case review of two infants who received a prolonged course of prostaglandin-E2 therapy for congenital cardiac lesions while awaiting corrective surgery. These cases highlight an association between prolonged prostaglandin-E2 therapy with periosteal reactions and elevated C-reactive protein levels. Failure to recognise this association may lead to multiple courses of antibiotics for presumed sepsis and further prolongation of prostaglandin-E2 therapy.
No takes yet. Share an insight, caveat, or question.
Duggan et al. (2017) conducted a case report in Congenital cardiac lesions (n=2). Prolonged prostaglandin-E2 therapy was evaluated on Periosteal reactions and elevated C-reactive protein levels. Prolonged prostaglandin-E2 therapy in infants with congenital cardiac lesions was associated with periosteal reactions and elevated C-reactive protein levels.
Synapse has enriched 10 related papers. Consider them for comparative context: